B7-33
Relaxin analogue
Single-chain relaxin-2 B-chain-based peptide, a functionally selective RXFP1 agonist studied preclinically; short half-life led to lipidated forms.
Evidence level. Evidence comes mainly from animal or other preclinical models. About the badges
- Class
- Relaxin analogue
- Category
- Antioxidants & Specialty
- Type
- Single compound
- Development and regulatory status
- Not approved; preclinical research peptide
What researchers study
Single-chain peptide agonist based on the B-chain of human relaxin-2, reported as a functionally selective agonist of the relaxin receptor RXFP1. Its short serum half-life, about 6 minutes in vitro, has prompted lipidated analogues.
Research areas
- RXFP1 signalling in cell assays
- Fibrosis models
- Cardioprotection and heart-failure models
- Peptide stability and lipidation studies
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- cell culture
Fatty-acid conjugation raised the in vitro serum half-life of B7-33 from about 6 minutes to 60 minutes without altering activity
- review
Human relaxin-2 has strong anti-fibrotic, vasodilatory and cardioprotective effects, making RXFP1 a target of interest
